These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35281926)

  • 21. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study.
    Caldeira D; Rodrigues R; Abreu D; Anes AM; Rosa MM; Ferreira JJ
    Expert Opin Drug Saf; 2018 Apr; 17(4):339-345. PubMed ID: 29463153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
    Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
    CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database.
    Crisafulli S; Cutroneo PM; Verhamme K; Ferrajolo C; Ficarra V; Sottosanti L; Di Giovanni V; Spina E; Trifirò G
    Eur Urol Focus; 2022 Sep; 8(5):1424-1432. PubMed ID: 34275763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System.
    Velișcu EM; Liguori V; Anatriello A; Maniscalco GT; Cantone A; Di Costanzo L; Stefanelli P; Scavone C; Capuano A
    Pharmaceuticals (Basel); 2023 Jul; 16(8):. PubMed ID: 37630986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.
    Capogrosso Sansone A; Convertino I; Galiulo MT; Salvadori S; Pieroni S; Knezevic T; Mantarro S; Marino A; Hauben M; Blandizzi C; Tuccori M
    Drug Saf; 2017 Oct; 40(10):895-909. PubMed ID: 28681266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years.
    Andreaggi CA; Novak EA; Mirabile ME; Sampathkumar S; Gray MP; He M; Kane-Gill SL
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1627-1635. PubMed ID: 32851782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.
    Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
    Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
    BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018.
    Elsisi Z; Hincapie AL; Guo JJ
    Am Health Drug Benefits; 2020 May; 13(2):74-84. PubMed ID: 32724502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical adverse drug reactions: descriptive analysis of French reports.
    Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.